All News

Individuals with migraine who failed to respond to up to 4 previous migraine preventive treatments saw fewer monthly migraine and headache days after 1 infusion of Lu AG90222.

Based on its acceptance of the resubmission, FDA has assigned a PDUFA action goal date of January 31, 2025 for AXS-07.

The approval makes dupilumab available to treat uncontrolled CRSwNP in adolescents aged 12 to 17 years, expanding on the current approved range of 18 years and older.

Unawareness was highest among the youngest adults, aged 18 to 44 years, an age range where CV health should be optimized to avoid later morbidity, researchers wrote.

Boehringer Ingelheim announces plans to submit NDA for Investigational Therapy.

Approximately 10.5 million US adults, or 5% of the population, have the atrial fibrillation, according to new prevalence estimates.

The term "flare" is used consistently in discussions of AD, but is everyone talking about the same thing? New research closes in on a patient-centered definition.

Which state retains the most medical residents? Or has the lowest cancer rate? Answers and more insights from a nationwide analysis, here.

The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

The needle-free nasal spray, if approved, would be the first new administration method for epinephrine in young children in 35 years.

Regulations have been amended under the Mammography Quality Standards Act of 1992 to ensure women receive quality mammography for early breast cancer detection and prevention.

The cortisol deficiency central to congenital adrenal hyperplasia requires lifelong treatment with distinct shifts in management required at each developmental stage.

Your daily dose of the clinical news you may have missed.

In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.

The new data amend that from prelicensure trials, which did not include fair representation of older adults and others more vulnerable to severe RSV disease.

Your daily dose of the clinical news you may have missed.

Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.